An interventional study of High Flow Nasal Cannula and "Intrinseque Health" Non-Rebreathing Mask ("IHNRM") in Respiratory Disease, Respiratory Distress Syndrome and Respiratory Failure, sponsored by China Medical University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by China Medical University Hospital · Not applicable, Interventional, and Prevention
Based on early bench-testing data and subsequent clinical case studies in the U.S., "Intrinseque Health" non-rebreathing mask (IHNRM) has delivered virtual elimination of air entrainment and preferential delivery of all available oxygen first into the alveolar spaces by sequential opening of valves in its controller manifold, even at oxygen flow as low as 10 LPM, patient can attain high alveolar oxygen concentration of 75% or more-far higher than attainable with face mask or nasal cannula.
Numerous intubated patients emerging from the operating room require intensive critical care specialist supervision in order to transition to the regular care. This would enable higher patient turnover and more efficient utilization of hospital resources, if patient can be transited to the regular care earlier by using a device that supports high oxygenation. This will enable a faster, safe and smooth extubation in critical care, and earlier discharge from intensive care ward.
This study is anticipated to take only around 2.5 hour per patient to complete. Patients meeting the inclusion and exclusion criteria of this study are placed on IHNRM and monitored until steady state of SpO2 of 95% or higher on 7-10 LPM has been maintained for at least 2 hours, when they can be discharged from the post-anesthesia care unit (PACU) to the regular care ward.
The study is the parallel design study. 60 patients will be randomly selected to use the IHNRM, and 30 subjects will be placed on HFNC. Blood oxygen concentration (SpO2), respiratory rate, end tidal CO2 concentration (EtCO2), and vital sign will be recorded in the study. The endpoint of the study is to compare the effect after using between "IHNRM" and HFNC.
1,596 studies on the registry are indexed under Respiratory Distress Syndrome; 312 are open to participants now.
This study's planned enrollment of 90 is above the median of 60 across 960 interventional studies indexed under Respiratory Distress Syndrome.
Browse Respiratory Distress Syndrome studies →China Medical University Hospital is the lead sponsor of 464 studies on the registry; 116 are open to participants now.
Counted across the registry records on this site, refreshed daily.
ANY hospitalized patient in moderate to moderately severe respiratory distress and able to breathe spontaneously, and with SpO2 (oxygen saturation by pulse oximetry) reading of:
(i) 90% or less on room air, or (ii) \<95% in spite of oxygen supplementation on another form of oxygen supplementation.
Exclusion Criteria:
Patient with any of the following present will be excluded:
High Flow Nasal Cannula
Device: High Flow Nasal Cannula
"Intrinseque Health" Non-Rebreathing Mask ("IHNRM")
Device: "Intrinseque Health" Non-Rebreathing Mask ("IHNRM")
High Flow Nasal Cannula
"Intrinseque Health" Non-Rebreathing Mask ("IHNRM")
Time to reach SpO2 Criteria in Run-in
Time to attaining SpO2 is by 4 percentage points or more above the baseline SpO2 while on room air or ≥95% .
Time frame: SpO2 will be recorded in every 5 minutes in Run-in phase up to 30 minutes
The percentage of subjects to reach SpO2 Criteria in maintenance
Comparing % of patients able to maintain target parameters for a continuous duration of 2 hours or more the time of continuous SpO2 reading of 4 points or more above the baseline SpO2 while on room air or SpO2 reading ≥95%
Time frame: SpO2 will be recorded in every 30 minutes in maintenance phase up to 2 hours
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome→
China Medical University Hospital